NCT04398680
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04398680
Title A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function (DREAMM 13)
Acronym DREAMM 13
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GRC

Facility Status City State Zip Country Details
GSK Investigational Site Tucson Arizona 85724 United States Details
GSK Investigational Site Beverly Hills California 90211 United States Details
GSK Investigational Site Plantation Florida 33322 United States Details
GSK Investigational Site Wichita Kansas 67214 United States Details
GSK Investigational Site Baltimore Maryland 21201-1595 United States Details
GSK Investigational Site Monroeville Pennsylvania 15146 United States Details
GSK Investigational Site The Woodlands Texas 77380 United States Details
GSK Investigational Site Milwaukee Wisconsin 53233 United States Details
GSK Investigational Site Athens 10676 Greece Details
GSK Investigational Site Daegu 41944 South Korea Details
GSK Investigational Site Hwasun 58128 South Korea Details
GSK Investigational Site Incheon 405-760 South Korea Details
GSK Investigational Site Jeonju 561-172 South Korea Details
GSK Investigational Site Pusan 49241 South Korea Details
GSK Investigational Site Seoul 03080 South Korea Details
GSK Investigational Site Seoul 06591 South Korea Details
GSK Investigational Site Seoul 120-752 South Korea Details
GSK Investigational Site Suwon Kyunggi-do 16499 South Korea Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field